Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.65 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.65 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.65 |
| ▸ | HTR3A known ✓ | P46098 | 4/20 | 0.64 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.64 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.64 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.64 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.64 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.64 |
| ▸ | HTR7 known ✓ | P34969 | 5/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.57 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.57 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7757785 | 1.00 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL1706127 | 1.00 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL7838014 | 0.98 | ADRB1 (1.00) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL379449 | 0.98 | ADRB1 (1.00) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL5669070 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Bromide SCHEMBL27617608 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Bromide SCHEMBL4875933 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Piperazine SCHEMBL28092166 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL4526848 | 0.92 | ADRB1 (0.88) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL11074672 | 0.85 | ADRB1 (0.76) | ADRB1NPC1MAPTDRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0091511-A2 | 1-(3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and -piperidines, a process for the preparation thereof, pharmaceutical compositions containing the same and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-10-19 | — | — | EP | claimed |
| CN-119798172-A | Preparation method of Leitemivir key intermediate dihydroquinazoline ester | 仁合益康集团有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-118084807-A | Refining method of 3, 4-dihydro quinazoline compound | 南京正大天晴制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11851435-B2 | PTGR2 inhibitors and their use | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-12-26 | — | — | US | disclosed |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | NATIONAL TAIWAN UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| CN-115850192-A | Process for preparing 3,4-dihydroquinazoline derivatives | 南京正大天晴制药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-9670202-B2 | Substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-06 | — | — | US | disclosed |
| CN-105408332-B | Substituted triazolopyridines | 拜耳制药股份公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-3004092-B1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| EP-0316723-A1 | 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-05-24 | — | — | EP | disclosed |
| EP-0091511-B1 | 1-(3-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PROPYL)-4-(SUBSTITUTED)-PIPERAZINES AND -PIPERIDINES, A PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4707550-A | N-(substituted thienyl)-N'-(substituted piperazinyl)-ureas | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0244176-A2 | Thienopyrimidine-2,4-dione derivatives and intermediates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4670560-A | VASODILATING AGENTS, HYPOTENSIVE AGENTS AND/OR CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-02 | — | — | US | disclosed |
| US-4610988-A | HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-09-09 | — | — | US | disclosed |
| US-4609658-A | ANTIPSYCHOTIC, ANALGESIC | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-09-02 | — | — | US | disclosed |
| US-4604395-A | NERVOUS SYSTEM DISORDERS, ANALGESICS, HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4536578-A | ANTIHALLUCINOGENS, HYPOTENSIVE AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-08-20 | — | — | US | disclosed |
| US-4140775-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851435-B2 | PTGR2 inhibitors and their use | PTGFR, PTGIR, PTGDR2 | ADRB1 128/4885HTR2C 341/4885HTR1A 294/4885 |
| US-20230279008-A1 | PTGR2 INHIBITORS AND THEIR USE | PTGFR, PTGIR, PTGDR2 | ADRB1 128/4885HTR2C 341/4885HTR1A 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.